| MDL | - |
|---|---|
| Molecular Weight | 445.53 |
| Molecular Formula | C26H28FN5O |
| SMILES | O=C1NC2=C(C=C(NC3CCN(CC)CC3)C=C2)/C1=C(C4=CC=CC(F)=C4)/C5=NC=C(C)N5 |
|
Flt-1 4 nM (IC 50 ) |
KDR 20 nM (IC 50 ) |
PDGFRα 4 nM (IC 50 ) |
FGFR1 2 nM (IC 50 ) |
Tyrosine kinase-IN-1 is from reference (compound 8K) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Tyrosine kinase-IN-1 shows a reasonable PK profile (AUC( 0–∞ )=1.9, t 1/2 =4.6 h). It has a favorable oral bioavailability (F=63%) in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : ≥ 62.5 mg/mL ( 140.28 mM )
* "≥" means soluble, but saturation unknown.
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2445 mL | 11.2226 mL | 22.4452 mL |
| 5 mM | 0.4489 mL | 2.2445 mL | 4.4890 mL |
| 10 mM | 0.2245 mL | 1.1223 mL | 2.2445 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution